Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
The employee awards create potential dilution through options covering up to 213,300 common shares.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Syndax Pharmaceuticals (SNDX) granted inducement stock options covering up to 213,300 common shares on October 1, 2026, to new employees.
The awards went to nine employees under the company's 2023 Inducement Plan. Options vest over four years: 25% on the first anniversary of the vesting commencement date, then 1/48th monthly over 36 months. Vesting requires continued service with Syndax through each applicable vesting date.
Positive
- None.
Negative
- Minor point. Forward-looking: it has not happened yet and may not happen.Stock options covering up to 213,300 common shares create potential dilution as employees exercise vested awards.
Key Figures
- Inducement option shares
- Up to 213,300 shares
- Granted to new employees under the 2023 Inducement Plan
- Recipients
- 9 employees
- New employees receiving inducement awards
- Vesting period
- 4 years
- Stock options, subject to continued service
- Initial vesting
- 25%
- Vests on the one-year anniversary of the vesting commencement date
- Subsequent vesting
- 1/48th monthly over 36 months
- Remaining option shares vest monthly, subject to continued service
Historical Context
-
Prior awards covered up to 175,000 shares for 19 employees under the same plan.
-
Prior awards covered up to 59,250 shares for five employees under the same plan.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
NEW YORK, Oct. 02, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that on October 1, 2026, the Company granted inducement awards to purchase up to 213,300 shares of common stock to nine new employees under the Company's 2023 Inducement Plan. The stock options will vest over four years, with
About Syndax
Syndax Pharmaceuticals is a commercial-stage biopharmaceutical company advancing innovative cancer therapies. Highlights of the Company's pipeline include Revuforj® (revumenib), an FDA-approved menin inhibitor, and Niktimvo™ (axatilimab-csfr), an FDA-approved monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor. Fueled by our commitment to reimagining cancer care, Syndax is working to unlock the full potential of its pipeline and is conducting several clinical trials across the continuum of treatment. For more information, please visit www.syndax.com or follow the Company on X and LinkedIn.
Syndax Contact
Sharon Klahre
Syndax Pharmaceuticals, Inc.
sklahre@syndax.com
Tel 781.684.9827
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
How many inducement stock options did Syndax grant to new employees?
Syndax granted inducement stock options to purchase up to 213,300 common shares to nine new employees on October 1, 2026. The awards were granted under the company's 2023 Inducement Plan.